.webp)
Sphere Bio partners with Redbert to expand single-cell tech across China’s growing biopharma market.
Sphere Bio, the leader of picodroplet-based microfluidics for functional single-cell analysis and isolation, has appointed Redbert Biotechnology as its sole distribution partner in China. The strategic partnership highly enhances Sphere Bio's presence in the life sciences and biopharma market in one of the world's most vibrant markets.
The partnership favors Sphere Bio's further international growth, especially in the Asia-Pacific markets, due to increasing demand for its next-generation platforms. They range from the Cyto-Mine Chroma multiplexing system, a high-speed system capable of high-throughput functional screening for cell therapy use, cell line development, and antibody discovery.
Redbert Biotechnology, based in Beijing and with offices across China, offers deep experience in bioprocessing, specifically antibody discovery and cell line engineering—foundational uses in biopharmaceutical R&D. Their strong relationships with CDMOs, CROs, and research institutions make them an optimal partner to expand access to Sphere Bio's advanced technologies in the Chinese market.
To spearhead the initiative, Sphere Bio has hired Johnathan Fu as Country Manager – China and Hong Kong. With close to two decades of commercial leadership experience at firms such as 10x Genomics, Roche Diagnostics, and Bio-Rad, Fu will collaborate closely with Redbert to develop a strong commercial and technical support infrastructure in the region.
By combining Sphere Bio's technology with Redbert's local presence, the partnership will provide innovative single-cell and cell-based solutions to China's growing biopharma market by catalyzing therapeutic antibody innovation, precision medicine, and cell engineering.
This expansion is further evidence of Sphere Bio's commitment to advancing life science innovation globally and expanding its presence in translational and clinical research markets.
.webp)
.webp)
